Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Other Income / Expenses · Q4 FY2026 · quarter ended Sep 2026

Other income / expenses turns positive

Q4 FY2026 other income / expenses was $915K, compared with -$7.99M a year earlier. Trailing-twelve-month other income / expenses was -$16.74M.

Context

  • Other income / expenses amounted to 3.7% of revenue in FY2026, down 1.9 pp from a year earlier.
  • Other income / expenses grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly other income / expenses holds near $915K or moves back toward the trailing-twelve-month quarterly average of -$4.19M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$915K+110.4% QoQ
Last fiscal yearSep 2026
-$16.74M+64.2% YoY
LTMSep 2026
-$16.74M+64.2% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+111.5%——
1 year+64.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2026
(16.74M) USD
Year-over-year change
+64.2%

Other Income / Expenses vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +64.2% is the highest of 6, against a peer median of -1.0%.
  • Other income / expenses amounts to 3.7% of revenue for ARWR, versus a peer median of 12.4%.
ARWR Competitors
Other Income / Expenses for ARWR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$21.61M USD+11.8%-76.4%2.3%
WVEWave Life Sciences Ltd.LTM Mar 2026$13.29M USD-1.0%+91.1%18.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$10.54M USD-22.0%—23.2%
SLNSilence Therapeutics plcLTM Mar 2026$1.43M USD—-50.1%155.2%
PRQRProQR Therapeutics N.V.LTM Mar 2026€840.44K EUR-70.3%+16.3%6.3%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$16.74M USD+64.2%—3.7%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026-$200.21M USD-0.4%—4.2%
Peer median (excluding ARWR) —-1.0%-16.9%12.4%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.